{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:58:03Z","timestamp":1785452283833,"version":"3.56.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004515","name":"Universiti Kebangsaan Malaysia","doi-asserted-by":"publisher","award":["DCP-2017-010\/1"],"award-info":[{"award-number":["DCP-2017-010\/1"]}],"id":[{"id":"10.13039\/501100004515","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004515","name":"Universiti Kebangsaan Malaysia","doi-asserted-by":"publisher","award":["PP-2025-021"],"award-info":[{"award-number":["PP-2025-021"]}],"id":[{"id":"10.13039\/501100004515","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bioprocess Biosyst Eng"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00449-026-03377-9","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:07:22Z","timestamp":1783573642000},"page":"2101-2117","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Techno-economic evaluation of Islamic-compliant cell-based influenza vaccine production using AGE1.CR cell line in comparison to the current production using MDCK cell line"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8979-0472","authenticated-orcid":false,"given":"Nurul Nadiah","family":"Zulkarnain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurina","family":"Anuar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norliza","family":"Abd. Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Nazir","family":"Alias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peer Mohamed","family":"Abdul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazahiyah","family":"Ahmad Rodzli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siti Rozaimah","family":"Sheikh Abdullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"3377_CR1","unstructured":"World Health Organization (2024) Vaccines and immunization: What is vaccination? https:\/\/www.who.int\/news-room\/questions-and-answers\/item\/vaccines-and-immunization-what-is-vaccination. Accessed 8 Oct 2025"},{"key":"3377_CR2","doi-asserted-by":"publisher","first-page":"651","DOI":"10.2217\/fvl.10.46","volume":"5","author":"BE Johansson","year":"2010","unstructured":"Johansson BE, Eichelberger MC (2010) Influenza: a unique problem in vaccination. Future Virol 5:651\u2013664. https:\/\/doi.org\/10.2217\/fvl.10.46","journal-title":"Future Virol"},{"key":"3377_CR3","doi-asserted-by":"publisher","first-page":"4638","DOI":"10.1002\/JMV.26990","volume":"93","author":"M Javanian","year":"2021","unstructured":"Javanian M, Barary M, Ghebrehewet S et al (2021) A brief review of influenza virus infection. J Med Virol 93:4638\u20134646. https:\/\/doi.org\/10.1002\/JMV.26990","journal-title":"J Med Virol"},{"key":"3377_CR4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/nyas.12462","volume":"1323","author":"RG Webster","year":"2014","unstructured":"Webster RG, Govorkova EA (2014) Continuing challenges in influenza. Ann N Y Acad Sci 1323:115\u2013139. https:\/\/doi.org\/10.1111\/nyas.12462","journal-title":"Ann N Y Acad Sci"},{"key":"3377_CR5","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMOA2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu N, Zhang D, Wang W et al (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382:727\u2013733. https:\/\/doi.org\/10.1056\/NEJMOA2001017","journal-title":"N Engl J Med"},{"key":"3377_CR6","unstructured":"World Health Organization (2025) Influenza (seasonal). https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/influenza-%28seasonal). Accessed 8 Oct 2025"},{"key":"3377_CR7","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2373521","author":"T Zinnecker","year":"2024","unstructured":"Zinnecker T, Reichl U, Genzel Y (2024) Innovations in cell culture-based influenza vaccine manufacturing-from static cultures to high cell density cultivations. Hum Vaccin Immunother. https:\/\/doi.org\/10.1080\/21645515.2024.2373521","journal-title":"Hum Vaccin Immunother"},{"key":"3377_CR8","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1701912","author":"A P\u00e9rez-Rubio","year":"2020","unstructured":"P\u00e9rez-Rubio A, Ancochea J, Eiros Bouza JM (2020) Quadrivalent cell culture influenza virus vaccine. Comparison to egg-derived vaccine. Hum Vaccin Immunother. https:\/\/doi.org\/10.1080\/21645515.2019.1701912","journal-title":"Hum Vaccin Immunother"},{"key":"3377_CR9","doi-asserted-by":"publisher","first-page":"241","DOI":"10.37201\/REQ\/117.2021","volume":"35","author":"J\u00c1 Alde\u00e1n","year":"2022","unstructured":"Alde\u00e1n J\u00c1, Salamanca I, Oca\u00f1a D et al (2022) Effectiveness of cell culture-based influenza vaccines compared with egg-based vaccines: What does the literature say? Rev Esp Quimioter 35:241. https:\/\/doi.org\/10.37201\/REQ\/117.2021","journal-title":"Rev Esp Quimioter"},{"key":"3377_CR10","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1080\/21645515.2020.1865044","volume":"17","author":"NN Zulkarnain","year":"2021","unstructured":"Zulkarnain NN, Anuar N, Abd. Rahman N et al (2021) Cell-based influenza vaccine: current production, halal status assessment, and recommendations towards Islamic-compliant manufacturing. Hum Vaccin Immunother 17:2158\u20132168. https:\/\/doi.org\/10.1080\/21645515.2020.1865044","journal-title":"Hum Vaccin Immunother"},{"key":"3377_CR11","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1016\/j.vaccine.2013.02.026","volume":"31","author":"JD Grabenstein","year":"2013","unstructured":"Grabenstein JD (2013) What the World\u2019s religions teach, applied to vaccines and immune globulins. Vaccine 31:2011\u20132023. https:\/\/doi.org\/10.1016\/j.vaccine.2013.02.026","journal-title":"Vaccine"},{"key":"3377_CR12","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2170660","author":"NA Muhammad Azami","year":"2023","unstructured":"Muhammad Azami NA, Abdullah N, Kamalul Ariffin AS et al (2023) Hepatitis B and influenza vaccination coverage in healthcare workers, the elderly, and patients with diabetes in Malaysia. Hum Vaccin Immunother. https:\/\/doi.org\/10.1080\/21645515.2023.2170660","journal-title":"Hum Vaccin Immunother"},{"key":"3377_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jiph.2017.09.007","volume":"11","author":"A Ahmed","year":"2018","unstructured":"Ahmed A, Lee KS, Bukhsh A et al (2018) Outbreak of vaccine-preventable diseases in Muslim majority countries. J Infect Public Health 11:153\u2013155. https:\/\/doi.org\/10.1016\/j.jiph.2017.09.007","journal-title":"J Infect Public Health"},{"key":"3377_CR14","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1080\/21645515.2019.1706935","volume":"16","author":"LP Wong","year":"2020","unstructured":"Wong LP, Wong PF, AbuBakar S (2020) Vaccine hesitancy and the resurgence of vaccine preventable diseases: the way forward for Malaysia, a Southeast Asian country. Hum Vaccin Immunother 16:1511\u20131520. https:\/\/doi.org\/10.1080\/21645515.2019.1706935","journal-title":"Hum Vaccin Immunother"},{"key":"3377_CR15","doi-asserted-by":"publisher","first-page":"4499","DOI":"10.1016\/j.vaccine.2010.04.043","volume":"28","author":"LP Wong","year":"2010","unstructured":"Wong LP, Sam IC (2010) Factors influencing the uptake of 2009 H1N1 influenza vaccine in a multiethnic Asian population. Vaccine 28:4499\u20134505. https:\/\/doi.org\/10.1016\/j.vaccine.2010.04.043","journal-title":"Vaccine"},{"key":"3377_CR16","unstructured":"DinarStandard (2025) State of the global islamic economy report 2024\/2025. From crisis to catalyst: evolving Islamic economy opportunities. DinarStandard, Jakarta"},{"key":"3377_CR17","doi-asserted-by":"publisher","DOI":"10.1088\/1757-899X\/778\/1\/012029","volume":"778","author":"FN Aliya Mohamad Ros","year":"2020","unstructured":"Aliya Mohamad Ros FN, Abd Rahman N, Mohd Ali J et al (2020) Comparative study between avian cell and mammalian cell in production of influenza vaccine shariah compliance. IOP Conf Ser Mater Sci Eng 778:012029. https:\/\/doi.org\/10.1088\/1757-899X\/778\/1\/012029","journal-title":"IOP Conf Ser Mater Sci Eng"},{"key":"3377_CR18","doi-asserted-by":"publisher","first-page":"707","DOI":"10.17576\/jkukm-2020-32(4)-21","volume":"32","author":"FNA Mohamad Ros","year":"2020","unstructured":"Mohamad Ros FNA, Abd Rahman N, Anuar N et al (2020) Simulation for production of syariah-compliant influenza vaccine using trypsin and acutase in batch reactor via SuperPro Designer. Jurnal Kejuruteraan 32:707\u2013713. https:\/\/doi.org\/10.17576\/jkukm-2020-32(4)-21","journal-title":"Jurnal Kejuruteraan"},{"key":"3377_CR19","doi-asserted-by":"crossref","unstructured":"Ros FNAM, Rahman NAbd, Ali JM, et al (2021) Utilization of bioreactor operation mode in producing influenza vaccine syariah-compliant. In: Enhancing halal sustainability. Springer Singapore, Singapore, pp 259\u2013268","DOI":"10.1007\/978-981-33-4854-7_22"},{"key":"3377_CR20","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00253-010-2742-9","volume":"88","author":"Y Genzel","year":"2010","unstructured":"Genzel Y, Dietzsch C, Rapp E et al (2010) MDCK and Vero cells for influenza virus vaccine production: a one-to-one comparison up to lab-scale bioreactor cultivation. Appl Microbiol Biotechnol 88:461\u2013475. https:\/\/doi.org\/10.1007\/s00253-010-2742-9","journal-title":"Appl Microbiol Biotechnol"},{"key":"3377_CR21","doi-asserted-by":"publisher","first-page":"6256","DOI":"10.1016\/j.vaccine.2010.07.004","volume":"28","author":"V Lohr","year":"2010","unstructured":"Lohr V, Genzel Y, Behrendt I et al (2010) A new MDCK suspension line cultivated in a fully defined medium in stirred-tank and wave bioreactor. Vaccine 28:6256\u20136264. https:\/\/doi.org\/10.1016\/j.vaccine.2010.07.004","journal-title":"Vaccine"},{"key":"3377_CR22","doi-asserted-by":"publisher","first-page":"4975","DOI":"10.1016\/j.vaccine.2009.05.083","volume":"27","author":"V Lohr","year":"2009","unstructured":"Lohr V, Rath A, Genzel Y et al (2009) New avian suspension cell lines provide production of influenza virus and MVA in serum-free media: studies on growth, metabolism and virus propagation. Vaccine 27:4975\u20134982. https:\/\/doi.org\/10.1016\/j.vaccine.2009.05.083","journal-title":"Vaccine"},{"key":"#cr-split#-3377_CR23.1","doi-asserted-by":"crossref","unstructured":"Lohr V, Rath A, Jordan I, et al (2012) Avian designer cells AGE1.CR\u00ae as candidates for MVA and influenza vaccine production. In: Jenkins N, Barron NAP","DOI":"10.1007\/978-94-007-0884-6_102"},{"key":"#cr-split#-3377_CR23.2","unstructured":"(ed) Proceedings of the 21st Annual Meeting of the European Society for Animal Cell Technology (ESACT), Dublin, Ireland, June 7-10, 2009. Springer, Dordrecht, pp 615-631"},{"key":"3377_CR24","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/bit.260460206","volume":"46","author":"R Kempken","year":"1995","unstructured":"Kempken R, Preissmann A, Berthold W (1995) Assessment of a disc stack centrifuge for use in mammalian cell separation. Biotechnol Bioeng 46:132\u2013138. https:\/\/doi.org\/10.1002\/bit.260460206","journal-title":"Biotechnol Bioeng"},{"key":"3377_CR25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/bit.20599","volume":"92","author":"SR Wickramasinghe","year":"2005","unstructured":"Wickramasinghe SR, Kalbfu\u00df B, Zimmermann A et al (2005) Tangential flow microfiltration and ultrafiltration for human influenza A virus concentration and purification. Biotechnol Bioeng 92:199\u2013208. https:\/\/doi.org\/10.1002\/bit.20599","journal-title":"Biotechnol Bioeng"},{"key":"3377_CR26","unstructured":"Milo R, Jorgensen P, Moran U, et al (2020) Size of MDCK (Madin Darby canine kidney) cell - Mammalian tissue culture cell - BNID 108927. In: BioNumbers. https:\/\/bionumbers.hms.harvard.edu\/bionumber.aspx?s=n&v=0&id=108927. Accessed 16 Mar 2020"},{"key":"3377_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6750-14-72","volume":"14","author":"V Lohr","year":"2014","unstructured":"Lohr V, H\u00e4dicke O, Genzel Y et al (2014) The avian cell line AGE1.CR.pIX characterized by metabolic flux analysis. BMC Biotechnol 14:72. https:\/\/doi.org\/10.1186\/1472-6750-14-72","journal-title":"BMC Biotechnol"},{"key":"3377_CR28","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1586\/erv.11.111","volume":"10","author":"MW Wolff","year":"2011","unstructured":"Wolff MW, Reichl U (2011) Downstream processing of cell culture-derived virus particles. Expert Rev Vaccines 10:1451\u20131475. https:\/\/doi.org\/10.1586\/erv.11.111","journal-title":"Expert Rev Vaccines"},{"key":"3377_CR29","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1128\/jvi.1.6.1207-1216.1967","volume":"1","author":"CB Reimer","year":"1967","unstructured":"Reimer CB, Baker RS, Van Frank RM et al (1967) Purification of large quantities of influenza virus by density gradient centrifugation. J Virol 1:1207\u20131216","journal-title":"J Virol"},{"key":"3377_CR30","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.chroma.2016.08.056","volume":"1465","author":"J Vajda","year":"2016","unstructured":"Vajda J, Weber D, Brekel D et al (2016) Size distribution analysis of influenza virus particles using size exclusion chromatography. J Chromatogr A 1465:117\u2013125. https:\/\/doi.org\/10.1016\/j.chroma.2016.08.056","journal-title":"J Chromatogr A"},{"key":"3377_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150700","volume":"11","author":"TC Kon","year":"2016","unstructured":"Kon TC, Onu A, Berbecila L et al (2016) Influenza vaccine manufacturing: effect of inactivation, splitting and site of manufacturing. Comparison of influenza vaccine production processes. PLoS ONE 11:e0150700. https:\/\/doi.org\/10.1371\/journal.pone.0150700","journal-title":"PLoS ONE"},{"key":"3377_CR32","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.provac.2012.04.015","volume":"6","author":"G Iyer","year":"2012","unstructured":"Iyer G, Ramaswamy S, Cheng KS et al (2012) Flow-through purification of viruses\u2014a novel approach to vaccine purification. Procedia Vaccinol 6:106\u2013112. https:\/\/doi.org\/10.1016\/j.provac.2012.04.015","journal-title":"Procedia Vaccinol"},{"key":"3377_CR33","doi-asserted-by":"publisher","first-page":"8682","DOI":"10.1128\/JVI.76.17.8682-8689.2002","volume":"76","author":"OP Zhirnov","year":"2002","unstructured":"Zhirnov OP, Ikizler MR, Wright PF (2002) Cleavage of influenza A virus hemagglutinin in human respiratory epithelium is cell associated and sensitive to exogenous antiproteases. J Virol 76:8682\u20138689. https:\/\/doi.org\/10.1128\/JVI.76.17.8682-8689.2002","journal-title":"J Virol"},{"key":"3377_CR34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/B978-0-323-35761-6.00007-9","volume-title":"Plotkin\u2019s vaccines","author":"TM Finn","year":"2018","unstructured":"Finn TM, Egan W (2018) Vaccine additives and manufacturing residuals in vaccines licensed in the United States. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM (eds) Plotkin\u2019s vaccines, 7th edn. Elsevier, Philadelphia, pp 75-83.e2","edition":"7"},{"key":"3377_CR35","volume-title":"Plant design and economics for chemical engineers","author":"MS Peters","year":"2003","unstructured":"Peters MS, Timmerhaus KD, West RE (2003) Plant design and economics for chemical engineers, 5th edn. McGraw-Hill Companies Inc, New York","edition":"5"},{"key":"3377_CR36","unstructured":"Centers for Disease Control and Prevention (2021) Current CDC Vaccine Price List . https:\/\/www.cdc.gov\/vaccines\/programs\/vfc\/awardees\/vaccine-management\/price-list\/index.html. Accessed 2 Jun 2021"},{"key":"3377_CR37","unstructured":"Merck (2020) Product Directory Home | Sigma-Aldrich. https:\/\/www.sigmaaldrich.com\/technical-service-home\/product-catalog.html. Accessed 29 Apr 2020"},{"key":"3377_CR38","unstructured":"ThermoFisher Scientific (2020) Adenovirus Expression Medium (AEM), for PER.C6TM cells. https:\/\/www.thermofisher.com\/order\/catalog\/product\/12582011#\/12582011. Accessed 9 Sep 2020"},{"key":"3377_CR39","unstructured":"ATCC (2020) Cells and Microorganisms. https:\/\/www.atcc.org\/en\/Products\/Cells_and_Microorganisms.aspx. Accessed 8 Sep 2020"},{"key":"3377_CR40","unstructured":"PennState (2015) Pricing and Lead-Time. https:\/\/generalstores.psu.edu\/pricing-and-lead-time. Accessed 2 Apr 2021"},{"key":"3377_CR41","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.vaccine.2018.01.011","volume":"36","author":"J Sedita","year":"2018","unstructured":"Sedita J, Perrella S, Morio M et al (2018) Cost of goods sold and total cost of delivery for oral and parenteral vaccine packaging formats. Vaccine 36:1700\u20131709. https:\/\/doi.org\/10.1016\/j.vaccine.2018.01.011","journal-title":"Vaccine"},{"key":"3377_CR42","unstructured":"Nur Auni Arina MA, Hafizah AR, Norsyazmira Elia S, et al (2014) Pengurusan sisa merbahaya. https:\/\/www.slideshare.net\/amirakhair\/pengurusan-sisa-merbahaya. Accessed 2 Jun 2021"},{"key":"3377_CR43","unstructured":"Inland Revenue Board of Malaysia (2020) Kadar Cukai Pendapatan. http:\/\/www.hasil.gov.my\/bt_goindex.php?bt_kump=5&bt_skum=1&bt_posi=2&bt_unit=5000&bt_sequ=11&bt_lgv=1. Accessed 2 Jun 2021"},{"key":"3377_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.126839","volume":"51","author":"J Taaffe","year":"2025","unstructured":"Taaffe J, Goldin S, Lambach P, Sparrow E (2025) Global production capacity of seasonal and pandemic influenza vaccines in 2023. Vaccine 51:126839. https:\/\/doi.org\/10.1016\/j.vaccine.2025.126839","journal-title":"Vaccine"},{"key":"3377_CR45","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrmicro.2017.118","volume":"16","author":"VN Petrova","year":"2018","unstructured":"Petrova VN, Russell CA (2018) The evolution of seasonal influenza viruses. Nat Rev Microbiol 16:47\u201360. https:\/\/doi.org\/10.1038\/nrmicro.2017.118","journal-title":"Nat Rev Microbiol"},{"key":"3377_CR46","first-page":"17","volume":"36","author":"J Matthew","year":"2006","unstructured":"Matthew J (2006) Egg-based production of influenza vaccine: 30 years of commercial experience. The Bridge 36:17\u201324","journal-title":"The Bridge"},{"key":"3377_CR47","doi-asserted-by":"publisher","DOI":"10.17226\/26285","volume-title":"Globally resilient supply chains for seasonal and pandemic influenza vaccines","author":"R Anupindi","year":"2022","unstructured":"Anupindi R, Yadav P, Jefferson KMP, Ashby E (2022) Globally resilient supply chains for seasonal and pandemic influenza vaccines. National Academies Press, Washington, D.C."},{"key":"3377_CR48","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2217\/fmb.10.161","volume":"6","author":"JP Gregersen","year":"2011","unstructured":"Gregersen JP, Schmitt HJ, Trusheim H, Br\u00f6ker M (2011) Safety of MDCK cell culture-based influenza vaccines. Future Microbiol 6:143\u2013152. https:\/\/doi.org\/10.2217\/fmb.10.161","journal-title":"Future Microbiol"},{"key":"3377_CR49","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/J.BIOLOGICALS.2010.04.003","volume":"38","author":"D Onions","year":"2010","unstructured":"Onions D, Egan W, Jarrett R et al (2010) Validation of the safety of MDCK cells as a substrate for the production of a cell-derived influenza vaccine. Biologicals 38:544\u2013551. https:\/\/doi.org\/10.1016\/J.BIOLOGICALS.2010.04.003","journal-title":"Biologicals"},{"key":"3377_CR50","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000481","volume":"4","author":"S B\u00fchler","year":"2019","unstructured":"B\u00fchler S, Ramharter M (2019) Flucelvax Tetra: a surface antigen, inactivated, influenza vaccine prepared in cell cultures. ESMO Open 4:e000481. https:\/\/doi.org\/10.1136\/esmoopen-2018-000481","journal-title":"ESMO Open"},{"key":"3377_CR51","unstructured":"Standards Malaysia (2019) Halal Pharmaceuticals- General requirements (First revision) MS2424:2019. Department of Standards Malaysia, Cyberjaya"},{"key":"3377_CR52","first-page":"588","volume":"6","author":"RR Nasaruddin","year":"2012","unstructured":"Nasaruddin RR, Fuad F, Mel M et al (2012) The importance of a standardized Islamic manufacturing (IMP) for food and pharmaceutical productions. Adv Nat Appl Sci 6:588\u2013595","journal-title":"Adv Nat Appl Sci"},{"key":"3377_CR53","volume-title":"Production of trivalent influenza vaccines: disposable technology and insect cell lines","author":"AW Woolley","year":"2014","unstructured":"Woolley AW, Schlup J (2014) Production of trivalent influenza vaccines: disposable technology and insect cell lines. Kansas State University, Manhattan"},{"key":"3377_CR54","volume-title":"Production of new generation of influenza vaccine using; \u201cInsect Cell Method\u201d","author":"V Asryan","year":"2019","unstructured":"Asryan V, Castaneda S, De Keyser S et al (2019) Production of new generation of influenza vaccine using; \u201cInsect Cell Method.\u201d University of California, Riverside"},{"key":"3377_CR55","volume-title":"Influenza vaccine economics","author":"A Honeycutt","year":"2005","unstructured":"Honeycutt A, Robinson T, Layton C (2005) Influenza vaccine economics. RTI International, North Carolina"},{"key":"3377_CR56","unstructured":"Pandey S, Manjrekar S, Sumant O (2019) Influenza Vaccine Market Size, Share | Industry Forecast By 2026. In: Allied Market Research. https:\/\/www.alliedmarketresearch.com\/influenza-vaccines-market. Accessed 27 Nov 2020"},{"key":"3377_CR57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057755","volume":"8","author":"ES Pronker","year":"2013","unstructured":"Pronker ES, Weenen TC, Commandeur H et al (2013) Risk in Vaccine research and development quantified. PLoS ONE 8:e57755. https:\/\/doi.org\/10.1371\/journal.pone.0057755","journal-title":"PLoS ONE"},{"key":"3377_CR58","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1016\/j.vaccine.2017.06.003","volume":"35","author":"S Plotkin","year":"2017","unstructured":"Plotkin S, Robinson JM, Cunningham G et al (2017) The complexity and cost of vaccine manufacturing\u2014an overview. Vaccine 35:4064\u20134071. https:\/\/doi.org\/10.1016\/j.vaccine.2017.06.003","journal-title":"Vaccine"},{"key":"3377_CR59","doi-asserted-by":"publisher","first-page":"e1386","DOI":"10.1016\/S2214-109X(18)30346-2","volume":"6","author":"D Gouglas","year":"2018","unstructured":"Gouglas D, Le Thanh T, Henderson K et al (2018) Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study. Lancet Glob Health 6:e1386\u2013e1396. https:\/\/doi.org\/10.1016\/S2214-109X(18)30346-2","journal-title":"Lancet Glob Health"},{"key":"3377_CR60","first-page":"189","volume":"47","author":"SS Maitra","year":"2005","unstructured":"Maitra SS, Verma AK (2005) Process economics of recombinant hepatitis-B vaccine production in India. Indian Chem Engr 47:189\u2013194","journal-title":"Indian Chem Engr"},{"key":"3377_CR61","doi-asserted-by":"publisher","first-page":"97","DOI":"10.31436\/iiumej.v13i1.299","volume":"13","author":"NHM Safri","year":"2012","unstructured":"Safri NHM, Mel M, Foo DCY et al (2012) Process modelling and debottlenecking study of a vaccine production. IIUM Eng J 13:97\u2013107. https:\/\/doi.org\/10.31436\/iiumej.v13i1.299","journal-title":"IIUM Eng J"},{"key":"3377_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6750-12-79","volume":"12","author":"V Lohr","year":"2012","unstructured":"Lohr V, Genzel Y, Jordan I et al (2012) Live attenuated influenza viruses produced in a suspension process with avian AGE1.CR.pIX cells. BMC Biotechnol 12:79. https:\/\/doi.org\/10.1186\/1472-6750-12-79","journal-title":"BMC Biotechnol"},{"key":"3377_CR63","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1007\/S00253-019-09694-2","volume":"103","author":"D V\u00e1zquez-Ram\u00edrez","year":"2019","unstructured":"V\u00e1zquez-Ram\u00edrez D, Jordan I, Sandig V et al (2019) High titer MVA and influenza A virus production using a hybrid fed-batch\/perfusion strategy with an ATF system. Appl Microbiol Biotechnol 103:3025. https:\/\/doi.org\/10.1007\/S00253-019-09694-2","journal-title":"Appl Microbiol Biotechnol"},{"key":"3377_CR64","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1016\/J.VACCINE.2014.02.016","volume":"32","author":"Y Genzel","year":"2014","unstructured":"Genzel Y, Vogel T, Buck J et al (2014) High cell density cultivations by alternating tangential flow (ATF) perfusion for influenza A virus production using suspension cells. Vaccine 32:2770\u20132781. https:\/\/doi.org\/10.1016\/J.VACCINE.2014.02.016","journal-title":"Vaccine"},{"key":"3377_CR65","doi-asserted-by":"publisher","first-page":"4877","DOI":"10.1007\/S00253-020-10596-X","volume":"104","author":"G Gr\u00e4nicher","year":"2020","unstructured":"Gr\u00e4nicher G, Coronel J, Trampler F et al (2020) Performance of an acoustic settler versus a hollow fiber\u2013based ATF technology for influenza virus production in perfusion. Appl Microbiol Biotechnol 104:4877. https:\/\/doi.org\/10.1007\/S00253-020-10596-X","journal-title":"Appl Microbiol Biotechnol"}],"container-title":["Bioprocess and Biosystems Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00449-026-03377-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00449-026-03377-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00449-026-03377-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:04:37Z","timestamp":1785449077000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00449-026-03377-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":66,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["3377"],"URL":"https:\/\/doi.org\/10.1007\/s00449-026-03377-9","relation":{},"ISSN":["1615-7591","1615-7605"],"issn-type":[{"value":"1615-7591","type":"print"},{"value":"1615-7605","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}